Cervical Cancer Detection Articles & Analysis: Older
18 news found
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly ...
” According to the World Health Organization, cervical cancer is one of the most frequent cancers in women in the world and in China it is the second most common cancer among women. China has a population of approximately 560 million women above 15 years of age, who are at risk of developing cervical ...
According to the World Health Organization, cervical cancer is one of the most frequent cancers in women in the world and in China it is the second most common cancer among women. China has a population of approximately 560 million women above 15 years of age, who are at risk of developing cervical ...
” According to the World Health Organization, cervical cancer is one of the most frequent cancers in women in the world and in China it is the second most common cancer among women. China has a population of approximately 560 million women above 15 years of age, who are at risk of developing cervical ...
(OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, announced today that an independent study of 166 women in Hungary showed that LuViva detected 20% more cervical precancer and cancer than the HPV test. ...
” According to the World Health Organization, cervical cancer is ranked as one of the most frequent cancers in women in the world, and in China it is the second most common cancer among women. China has a population of approximately 560 million women above 15 years of age, who are at risk of developing ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly ...
This fraction of urine has shown to be a suitable sample type for detection of human papillomavirus (HPV) DNA, a major cause of cervical cancer. Urine is considered the preferred choice of self-sampling compared to other available methods used for cervical cancer screening. At-home urine self-sampling also ...
Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly ...
This is why the RIVM (the Dutch Health Institute responsible for the National Cervical Cancer Screening program) is looking for improved triage strategies for HPV positive screened women. ...
VisionGate is a clinical stage oncology pharmaceutical and diagnostics company focused on the early detection and prevention of cancer. Our lead investigative pharmaceutical drug is oral iloprost, currently in clinical development for the treatment of pre-cancerous bronchial dysplasia and the prevention of lung cancer following a ...
There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. About LuViva® Advanced Cervical Scan LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. ...
Food and Drug Administration (FDA) November 6, 2015, to review the company’s plan to submit an approvable application for the LuViva® Advanced Cervical Scan. The LuViva is designed to detect cervical pre-cancer without taking a tissue sample and providing a result immediately, unlike any other women’s health ...
Worldwide there are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer. About LuViva® Advanced Cervical Scan LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. ...
HPV testing identifies women with high-risk HPV DNA infections that can cause cervical cancer, enabling diagnosis and treatment to be put in place before cervical cancer develops. ...
The Royal Government of Bhutan, Merck (which is known as MSD outside the United States and Canada) and the Australian Cervical Cancer Foundation (ACCF) today launched a national vaccination program with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls and young women in Bhutan. In an effort to reduce the burden of cervical cancer, ...